HLA-C and neoplasm: Tumor Mutation Burden (TMB) is considered as a key driving factor for the immunogenicity of neoantigens presented on major histocompatibility complex (MHC) on the surface of tumor cells, which affects patients’ response to immune checkpoint inhibitors (ICIs) [43].